Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Short Interest Update

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) saw a large decline in short interest in February. As of February 13th, there was short interest totaling 1,852,420 shares, a decline of 20.6% from the January 29th total of 2,333,055 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average trading volume of 711,535 shares, the days-to-cover ratio is presently 2.6 days. Based on an average trading volume of 711,535 shares, the days-to-cover ratio is presently 2.6 days. Approximately 0.3% of the company’s shares are short sold.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.2%

FMS opened at $23.47 on Monday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.94 and a fifty-two week high of $30.46. The firm has a market capitalization of $13.60 billion, a PE ratio of 12.29, a P/E/G ratio of 0.71 and a beta of 0.91. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.26 and a quick ratio of 0.92. The company’s 50-day moving average is $23.30 and its 200 day moving average is $24.44.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.16. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%.The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $4.80 billion. As a group, research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Large investors have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth $36,000. CIBC Private Wealth Group LLC boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after purchasing an additional 1,103 shares during the last quarter. Atlantic Union Bankshares Corp bought a new stake in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth about $43,000. Arax Advisory Partners grew its position in Fresenius Medical Care AG & Co. KGaA by 121.6% in the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at about $48,000. 8.37% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, January 27th. Zacks Research lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Finally, The Goldman Sachs Group cut Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has an average rating of “Reduce” and an average target price of $28.00.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.